Effect of port-care frequency on venous port catheter-related complications in cancer patients
Authors:
- 27 August 2013
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 19 (4) , 761-766
Abstract
Purpose Subcutaneous central venous port catheters (SCVPC) are of great importance in the treatment of patients with malignancies since they provide secure vascular access. Our aim was to assess the impact of long-term catheter care frequency on the frequency of port-related complications. Patients and methods Two hundred and seven patients who had not been on active chemotherapy through their SCVPC for at least 3 months were enrolled into the study. Those who received catheter care every 3 months or more frequently were assigned to the frequent care group, and the others to the infrequent care group. The patients were examined for port-related complications and thrombosis including port occlusion. Routinely in our clinic, catheter care was done by using 300 IU of heparin. Results According to the frequency of SCVPC care, 49 (23.7 %) patients were in the frequent care group and 158 (76.3 %) were in the infrequent care group. Median follow-up of all patients was 671 days (range 133–1712). Median frequency of port care in the frequent care group was 90 days (range 30–90), but 441.5 days in the infrequent care group (range 91–1630). None of the patients experienced port-related severe complications during the follow-up time. None of them presented with port occlusion. When the groups were analysed for thrombus (symptomatic and asymptomatic), there was no statistically significant difference (6.4 vs 13.8 %, p = 0.17). Those patients who had received more than first-line chemotherapy were found to have more thrombi than the patients who were treated with only one type of chemotherapy protocol (28.6 vs 10.2 %, p = 0.01), and the patients who had metastatic disease at the last control were found out to have thrombi more frequently than the non-metastatic patients (24.3 vs 9.3 %) (p = 0.01). Conclusions In the present study, there was no difference in port-related severe complications between frequent and infrequent care groups during follow-up. However, the rate of thrombosis was slightly higher in the infrequent port care group.Keywords
This publication has 27 references indexed in Scilit:
- 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working groupAnnals of Oncology, 2009
- It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient settingSupportive Care in Cancer, 2008
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Thrombotic and infectious complications of central venous catheters in patients with hematological malignanciesAnnals of Oncology, 2007
- Low‐dose warfarin for the prevention of central line‐associated thromboses in children with malignancies—a randomized, controlled studyActa Paediatrica, 2006
- Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer PatientsJournal of Clinical Oncology, 2005
- How Often Should a Port-A-Cath be Flushed?Cancer Investigation, 2005
- Plasma Coagulation Markers in Patients with Solid Tumors and Venous Thromboembolic Disease Receiving Oral Anticoagulation TherapyClinical Cancer Research, 2004
- Long-term, totally implantable central venous access ports connected to a Groshong atheter for chemotherapy of solid tumours: Experience from 178 cases using a single type of deviceEuropean Journal of Cancer, 1997
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994